FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

To Observe the Pathological Remission Rate and Safety of FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer With a Single-arm, Open, Prospective Phase II Exploratory Clinical Study

The main cause of recurrence after surgical treatment of colorectal cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen the invasiveness of surgical resection. The FOLFOXIRI regimen has been shown to have a high objective efficiency in advanced colorectal cancer. This phase II trial is to explore the pathological remission rate and safety of stage II/III locally advanced colon cancer with high risk of recurrence to FOLFOXIRI regimen of neoadjuvant chemotherapy alone.

Study Overview

• Status: Recruiting
• Conditions: Neoadjuvant Chemotherapy; High-risk Locally Advanced Colorectal Cancer; FOLFOXIRI Regimen
• Intervention / Treatment: Drug: Oxaliplatin; Drug: Irinotecan; Drug: Folinic Acid; Drug: 5FU; Drug: Capecitabine

• Study Type: Interventional
• Enrollment (Anticipated): 69
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Meng Qiu, Ph.D; Phone Number: +8602885423203; Email: qiumeng@wchscu.cn
• Study Contact Backup: Name: Weibing Leng, Ph.D; Phone Number: +8602885423203; Email: s103470@stu.scu.edu.cn

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610044
      • Recruiting
      • Sichuan University West China Hospital
      • Contact: Weibing Leng; Phone Number: 18980601776; Email: s103470@stu.scu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age: 18-75 years old; Sex: Male or female;
• WHO performance status of 0, 1 or 2
• Histologically proven colorectal carcinoma (defined as cancer that is located >10 cm from the anal verge by endoscopy)
• Unequivocal radiological evidence of locally advanced cancer based on thin slice spiral CT [defined as T4a/b or (and) N2 / fused lymph nodes or (and) positive extramural vascular invasion (EMVI +) or (and) circumferential resection margin (CRM) ≤ 2mm].
• No distant metastases (distant organ or (and) distant lymph node metastases) assessed by CT scan or other radiographic examination.
• For patients with T4b, R0 resection was expected to be achieved, including the necessary combined organ resection，by MDT discussion.
• No history of 5-Fu and platinum drug allergy.
• Adequate bone marrow function: Hb>9g/dl; PLT >100 x 10^9/l; WBC >3.5 x 10^9/l and ANC ≥1.5x10^9/l.
• Adequate hepatobiliary function: ASAT (aspartate aminotransferase) and ALAT (alanine aminotransferase) of 2.5 x ULN (upper limits of normal) or less, Alkaline phosphatase of 2.5 x ULN or less, total bilirubin 1.5 x upper normal level or less.
• Adequate renal biochemistry: GFR >50 ml/min calculated by the Wright or Cockroft formula or EDTA clearance >70 ml/min.
• For female and of childbearing potential, patient must have a negative pregnancy test ≤72hours prior to initiating study treatment and agree to avoid pregnancy during and for 6 months after study treatment. For male with a partner of childbearing potential, patient must agree to use adequate, medically approved, contraceptive precautions during and for 90 days after the last dose of study treatment
• Patient able and willing to provide written informed consent for the study.

Exclusion Criteria:

• Patients with lynch syndrome
• Rectal cancer located 10 cm or less from the anal verge.
• Any patient for whom radiotherapy is advised by the MDT.
• Patient with evidence of distant metastases or peritoneal nodules (M1).
• Severe intestinal complications on initial clinical or imaging assessment: perforation, obstruction, uncontrollable bleeding.
• Another serious medical condition judged to compromise ability to tolerate neoadjuvant therapy and/or surgery.
• Pre-existing or concurrent other malignancies (including concurrent colon cancer), except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.
• Pregnant or breastfeeding women.
• Patients with severe cardiovascular disease and diabetes mellitus that cannot be easily controlled.
• Persons with mental disorders.
• Patients with severe infections.
• Patients on thrombolytic/anticoagulant therapy, bleeding quality or coagulation disorders; or aneurysms, strokes, transient ischemic attacks, arteriovenous malformations in the past year.
• Previous history of renal disease with urine protein on urinalysis or clinically significant renal function abnormalities.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Neoadjuvant chemotherapy; 4 cycles of neoadjuvant chemotherapy with FOLFOXIRI + operation + 5 cycles of adjuvant chemotherapy with XELOX

Drug: Oxaliplatin; Oxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery; Other Names: Eloxatin; Drug: Irinotecan; Irinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection; Other Names: Campto; Drug: Folinic Acid; Folinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection; Other Names: Leukovorin; Drug: 5FU; 5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection; Other Names: 5-Fluorouracil; Drug: Capecitabine; Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection; Other Names: Xeloda

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathological response	The rate of Tumor Regression Grade 0-1 in the resected tumour tissue	up to 24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	Rate of patients with partial or complete response according to modified RECIST criteria.	up to 24 weeks
Pathologic Complete Response (PCR)	Rate of pathological complete response in the resected tumour tissue	up to 24 weeks
R0 resection rate	Resection rate, defined as patients with microscopically complete (R0) resection (ITT- population)	up to 24 weeks
Progression Free Survival (PFS)	Progression free survival (Medium, Kaplan-Meier-estimation, ITT- population)	up to 3 years
Distant metastasis-free survival Metastasis-free survival	distant Distant metastasis-free survival (Medium, Kaplan-Meier-estimation, ITT- population)	up to 3 years
Overall survival	Overall survival (Kaplan-Meier-estimation, ITT- population)	up to 3 years
Toxicity and Compliance to study treatment	Toxicity according to NCI-CTC criteria v. 4.0 Perioperative toxicity according to Clavien	up to 1 years
Molecular markers	Evaluation of molecular predictive markers for response and toxicity	up to 1 years
Quality of Life to study treatment	scores of Quality of Life Questionare-Core 30 of the European Organization for Research and Treatment of Cancer	up to 1 years
Number of patients with 30-day post-operative mortality		up to 24 weeks

Collaborators and Investigators

• Sponsor: West China Hospital
• Investigators: Principal Investigator: Weibing Leng, Ph.D, Sichuan University

Study record dates

Study Major Dates

• Study Start (Actual): August 2, 2021
• Primary Completion (Anticipated): April 1, 2022
• Study Completion (Anticipated): August 2, 2022

Study Registration Dates

• First Submitted: August 3, 2021
• First Submitted That Met QC Criteria: August 18, 2021
• First Posted (Actual): August 24, 2021

Study Record Updates

• Last Update Posted (Actual): August 24, 2021
• Last Update Submitted That Met QC Criteria: August 18, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Protective Agents; Topoisomerase Inhibitors; Micronutrients; Vitamins; Topoisomerase I Inhibitors; Antidotes; Vitamin B Complex; Hematinics; Fluorouracil; Capecitabine; Oxaliplatin; Leucovorin; Irinotecan; Levoleucovorin; Folic Acid
• Other Study ID Numbers: 2021-010

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No